Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN5A | Q14524 | 3/20 | 0.59 |
| ▸ | SCN9A | Q15858 | 3/20 | 0.59 |
| ▸ | EPHX1 | P07099 | 3/20 | 0.39 |
| ▸ | KIF11 | P52732 | 1/20 | 0.38 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | CNR1 | P21554 | 1/20 | 0.35 |
| ▸ | CNR2 | P34972 | 1/20 | 0.35 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15875035 | 0.82 | CHRM2 (0.44) | SCN5ASCN9AMEN1KMT2ACNR1 | |
| SCHEMBL9277669 | 0.82 | CHRM2 (0.44) | SCN5ASCN9AMEN1KMT2ACNR1 | |
| SCHEMBL12267924 | 0.77 | SCN5A (0.65) | SCN5ASCN9AEPHX1KIF11SMN1; SMN2 | |
| SCHEMBL9000665 | 0.76 | CHRM2 (0.43) | KIF11MEN1KMT2ASMN1; SMN2ALDH1A1 | |
| SCHEMBL3359169 | 0.75 | SCN5A (0.78) | SCN5ASCN9AEPHX1KIF11EPHX2 | |
| SCHEMBL3359165 | 0.75 | SCN5A (0.78) | SCN5ASCN9AEPHX1KIF11EPHX2 | |
| SCHEMBL1712517 | 0.74 | SCN5A (1.00) | SCN5ASCN9AEPHX1KIF11EPHX2 | |
| SCHEMBL1712454 | 0.74 | SCN5A (1.00) | SCN5ASCN9AEPHX1KIF11EPHX2 | |
| SCHEMBL1712264 | 0.74 | SCN5A (1.00) | SCN5ASCN9AEPHX1KIF11EPHX2 | |
| SCHEMBL11492645 | 0.72 | POLB (0.43) | MEN1KMT2ASMN1; SMN2CNR2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8816095-B2 | Na channels, disease, and related assays and compositions | GEORGETOWN UNIVERSITY (US) | 2014-08-26 | — | — | US | disclosed |
| US-8816095-B2 | Na channels, disease, and related assays and compositions | GEORGETOWN UNIVERSITY (US) | 2014-08-26 | — | — | US | disclosed |
| US-20110230442-A1 | NA CHANNELS, DISEASE, AND RELATED ASSAYS AND COMPOSITIONS | GEORGETOWN UNIVERSITY (US) | 2011-09-22 | — | — | US | disclosed |
| US-20110230442-A1 | NA CHANNELS, DISEASE, AND RELATED ASSAYS AND COMPOSITIONS | GEORGETOWN UNIVERSITY (US) | 2011-09-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110230442-A1 | NA CHANNELS, DISEASE, AND RELATED ASSAYS AND COMPOSITIONS | CACNA1C, CACNA1B, CACNA1A | SCN5A 48/4885SCN9A 51/4885EPHX1 1123/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.